Suzhou Zelgen Biopharmaceuticals Co.,Ltd
82
23
28
31
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
11.0%
9 terminated/withdrawn out of 82 trials
77.5%
-9.0% vs industry average
16%
13 trials in Phase 3/4
0%
0 of 31 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (82)
A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.
Role: lead
A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors
Role: lead
Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma
Role: lead
Study of ZG005 in Patients With Advanced Solid Tumors
Role: lead
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
Role: lead
Study of ZGGS34 in Participants With Advanced Solid Tumors
Role: lead
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Role: lead
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Role: lead
Study of ZGGS18 in Patients With Advanced Solid Tumors
Role: lead
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Role: lead
Study of ZGGS15 in Patients With Advanced Solid Tumors
Role: lead
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Role: lead
Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)
Role: lead
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Role: lead
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
Role: lead
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Role: lead
A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis
Role: lead
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Role: lead
Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors
Role: lead
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
Role: lead